Repligen NASDAQ RGEN
$190.79 5.49 2.88%
Today share price
USA
Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free
Rating Finrange Index: 34 %
Market cap

Market capitalization – refers to the total value of all a company's shares of stock. It is calculated by multiplying the price of a stock by its total number of outstanding shares.

10.93B
EV

Enterprise value is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. Enterprise value includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.

10.59B
Beta

Beta is one of the most popular indicators of risk is a statistical measure. Analysts use this measure often when they need to determine a stock's risk profile.

0.87
Shares

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company’s insiders.

57.30M
YTD

Year to date (YTD) refers to the period of time beginning the first day of the current calendar year or fiscal year up to the current date. he acronym often modifies concepts such as investment returns and price change.

12.69 %
Upcoming events Repligen All events
No upcoming events scheduled

Stock chart Repligen

Stock analysis Repligen

Indicator Company Industry
P/E (LTM)

Shows how many years the investor's investment in the company will pay off with a profit over the last 12 months.

More
65.73 37.90
P/BV (LTM)

Shows the ratio of the market price of the share to the current book value.

More
6.25 6.07
EV/EBITDA (LTM)

Represents the ratio of the company's value to its pre-tax EBITDA in the last 12 months.

More
40.60 20.77
Net Debt/EBITDA (LTM)

A company's debt ratio, which indicates how long the company will need to run on cash flow in the past 12 months to pay off its own debt.

More
-1.30 0.24
ROE (LTM)

Shows the efficiency of using the share capital by the company. In other words, ROE shows how much of the company's net profit for the invested capital over the last 12 months.

More
9.06 16.61

Price change Repligen per year

162.29$ 327.32$
Min Max

Summary analysis Repligen

Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Shareholder structure Repligen

Revenue and net income Repligen

All parameters

About company Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company offers filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and SpectraFlo dynamic dialysis systems; and ProConnex single-use hollow fiber. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE and FlowVPE brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands; and Sartorius Stedim Biotech to create novel perfusion-enabled bioreactors. Repligen Corporation was incorporated in 1981 and is headquartered in Waltham, Massachusetts.
Address:
Building 1, Waltham, MA, United States, 02453
Company name: Repligen
Issuer ticker: RGEN
ISIN: US7599161095
Country: USA
Exchange: NASDAQ
Currency: $
IPO date: 1990-03-26
Sector: Healthcare
Industry: Life Sciences Tools & Services
Site: https://www.repligen.com

On which stock exchange are Repligen (RGEN) stocks traded?

Repligen (RGEN) stocks are traded on NASDAQ.

What is the ticker of Repligen stocks (RGEN)?

The stock ticker of Repligen’s stocks or in other words, the code is RGEN. The stocks are currently listed on the NASDAQ exchange.

In which sector and industry does Repligen (RGEN) operate?

According to the GICS (Global Industry Classification Standard) classification developed jointly by MSCI and Standard & Poor's, Repligen (RGEN) belongs to the «Healthcare» sector and the «Life Sciences Tools & Services» industry.

In what currency are Repligen (RGEN) stocks traded?

Repligen (RGEN) stocks are traded on the NASDAQ exchange in dollars.

What is the price of Repligen (RGEN) stocks today?

The current price of Repligen stocks on 02.02.2023 is 190.79 dollars. per share.

What is the dynamics of Repligen (RGEN) stocks from the beginning of the year?

Repligen (RGEN) quotes have increased by 23.68% from the beginning of the year up to 190.79 dollars. per 1 stocks.

How much did Repligen (RGEN) stocks increase in феврале 2023?

This month Repligen (RGEN) quotes have increased by 0% to 190.79 dollars. per share.

How much are Repligen (RGEN) stocks worth?

Today, on October, 02.02.2023 Repligen’s (RGEN) stocks cost 190.79 dollars..

What is the market capitalization of Repligen (RGEN)?

Capitalization is the market value of Repligen (RGEN) is calculated as the number of issued stocks multiplied on the current quotation price. Thus, on 02.02.2023, the market capitalization of Repligen (RGEN) is estimated at about 10933030160 dollars.